Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Samuel Wickline
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Entropy Vision, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Wickline's personal financial relationship with Entropy Vision, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• The primary focus of Entropy Vision, an entity with which Dr. Wickline owns equity, is to commercialize intellectual property, a transducer incorporating software developed at WU. The IP is being developed and evaluated in the above listed research.
• The determination for Entropy Vision to license the studied IP in the future will be in large part based on the outcomes of the research.
• Dr. Wickline's role as Principal Investigator in designing the study, collecting and analyzing data, reporting the results, oversight of the research, supervising individuals involved with the research, and as mentor could directly affect the outcome of the study.
While the CIRC determined a financial conflict of interest exists, it concluded there are mitigating factors that help address the situation:
a. The research is basic in nature and in its early phases.
b. Dr. Wickline is uniquely qualified by virtue of his expertise and experience, and the research could not be conducted as effectively without his involvement.
c. While there is the possibility for a license in the future based on the results of the study, there is no active license for the IP being studied.
d. Additionally, a plan has been developed to address Dr. Wickline's financial conflict of interest
REAL TIME ULTRASOUND ENTROPY-BASED QUANTIFICATION OF FIBROFATTY LIVER DISEASE
The major problem addressed in this proposal is the development and evaluation of a noninvasive ultrasonic diagnostic approach for mapping a set of unique and quantitative ultrasonic metrics for liver disease. These are anticipated to differentiate physiological from pathological liver microanatomy in patients with diverse liver diseases with the use of conventional ultrasound scanners and a novel signal processing methodology. The method is based on radiofrequency signal (RF) processing schemes referred to as information theoretic detectors (ITD's) that have been shown to detect pathological changes in muscle diseases and cancer by measuring selected signal entropies that may be translated to the clinic as cheap point-of-care approaches without the need for expensive imaging systems. As prevalence of liver disease increases with age (e.g. non alcoholic fatty liver disease: 9.7% among children, 26% among people 40-59 years old) the availability of a rapid, low- cost, point-of-care device for longitudinal diagnosis of liver pathologies would find widespread clinical application supporting the health and well-being of older adults.
Filed on July 01, 2015.
Tell us what you know about Samuel Wickline's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Samuel Wickline filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | $0 - $4,999 |
| Samuel Wickline | Washington University | Conflict of Interest | Entropy Vision, LLC | $0 - $4,999 |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq Inc. | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Acuplaq, Inc. | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
| Samuel Wickline | Washington University | Conflict of Interest | Trasir Therapeutics | Value cannot be readily determined |
| Samuel Wickline | University of South Florida | Conflict of Interest | AcuPlaq, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.